Onepot AI has emerged from stealth, announcing a $13 million funding round to overhaul the creation of complex chemical molecules essential for drug development. The funding round was led by Fifty Years.
Founders Daniil Boiko and Andrei Tyrin identified a critical friction point: promising drug candidates often stall because the necessary molecules are too difficult or time-consuming to synthesize in the lab. This synthesis bottleneck prevents valuable compounds from ever reaching biological testing phases.
The company combines advanced machine learning with a dedicated physical lab, POT-1, to bridge the gap between computational molecular design and tangible chemical reality. They developed an AI organic chemist named Phil to manage experimental analysis and optimize synthesis pathways.
Current industry standards rely heavily on months-long trial-and-error processes conducted by human chemists or outsourced to overseas contract research organizations. This traditional method is slow, expensive, and generates inconsistent data, severely limiting the pace of discovery.
Onepot AI promises to compress the timeline for creating specific compounds from months down to mere days for its biotech and pharma partners. Clients select target molecules from Onepot’s catalog, and the firm synthesizes and ships the physical product.
A core differentiator is the meticulous data capture within their automated lab environment, recording every variable like temperature and ingredient ratios for every reaction. This granular data feeds back into their system, ensuring every experiment is fully reproducible for future reference.
This approach allows their AI agents to generate hypotheses based on real-world laboratory execution rather than relying solely on potentially incomplete published literature. Consequently, Onepot is expanding the accessible chemical design space previously deemed infeasible.
The fresh capital will fund the construction of a second laboratory in San Francisco, enabling the company to onboard significantly more commercial clients. Key participants in the round included Khosla Ventures, Speedinvest, and notable AI figures like OpenAI co-founder Wojciech Zaremba and Google’s Jeff Dean.
Boiko and Tyrin anticipate their technology will accelerate drug discovery timelines by at least twofold. Their ultimate goal is to shift the paradigm, ensuring that innovative chemical structures are limited only by imagination, not synthetic feasibility.
